These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24510833)

  • 41. Parasitic infection and the polarized Th2 immune response can alter a vaccine-induced immune response.
    Robinson TM; Nelson RG; Boyer JD
    DNA Cell Biol; 2003 Jun; 22(6):421-30. PubMed ID: 12906735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolution of electroporated DNA vaccines.
    Keane-Myers AM; Bell M
    Methods Mol Biol; 2014; 1121():269-78. PubMed ID: 24510831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Electroporation delivery of DNA vaccines: prospects for success.
    Sardesai NY; Weiner DB
    Curr Opin Immunol; 2011 Jun; 23(3):421-9. PubMed ID: 21530212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adipose tissue: a new target for electroporation-enhanced DNA vaccines.
    Fisher PD; Brambila CJ; McCoy JR; Kiosses WB; Mendoza JM; Oh J; Yung BS; Schultheis K; Smith TRF; Broderick KE
    Gene Ther; 2017 Dec; 24(12):757-767. PubMed ID: 29106403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-1 DNA vaccines and chemokines.
    Boyer JD; Kim J; Ugen K; Cohen AD; Ahn L; Schumann K; Lacy K; Bagarazzi ML; Javadian A; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
    Vaccine; 1999 Oct; 17 Suppl 2():S53-64. PubMed ID: 10506409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNA vaccines: prime time is now.
    Gary EN; Weiner DB
    Curr Opin Immunol; 2020 Aug; 65():21-27. PubMed ID: 32259744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The diversity of HIV-1 fights against vaccine efficacy: how self-assembling protein nanoparticle technology may fight back.
    Karch CP; Burkhard P; Matyas GR; Beck Z
    Nanomedicine (Lond); 2021 Apr; 16(8):673-680. PubMed ID: 33715403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 vaccine--many miles to go before we sleep.
    Jeang KT; Huang LM
    J Formos Med Assoc; 2009 Nov; 108(11):827-9. PubMed ID: 19933024
    [No Abstract]   [Full Text] [Related]  

  • 49. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.
    Bodles-Brakhop AM; Heller R; Draghia-Akli R
    Mol Ther; 2009 Apr; 17(4):585-92. PubMed ID: 19223870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA vaccines: progress and challenges.
    Donnelly JJ; Wahren B; Liu MA
    J Immunol; 2005 Jul; 175(2):633-9. PubMed ID: 16002657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved DNA Vaccine Delivery with Needle-Free Injection Systems.
    Ledesma-Feliciano C; Chapman R; Hooper JW; Elma K; Zehrung D; Brennan MB; Spiegel EK
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Production of research-grade antibody by in vivo electroporation of DNA-encoding target protein.
    Okahara F; Itoh K; Ebihara M; Kobayashi M; Maruyama H; Kanaho Y; Maehama T
    Anal Biochem; 2005 Jan; 336(1):138-40. PubMed ID: 15582570
    [No Abstract]   [Full Text] [Related]  

  • 53. DNA vaccines: ready for prime time?
    Kutzler MA; Weiner DB
    Nat Rev Genet; 2008 Oct; 9(10):776-88. PubMed ID: 18781156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Introduction to fourth special issue on electroporation-based technologies and treatments.
    Miklavčič D; Mir LM; Vernier PT
    J Membr Biol; 2014 Dec; 247(12):1207-8. PubMed ID: 25359202
    [No Abstract]   [Full Text] [Related]  

  • 55. Promising HIV vaccines could stall without coordinated research.
    Maxmen A
    Nature; 2018 Mar; 555(7694):17-18. PubMed ID: 32094904
    [No Abstract]   [Full Text] [Related]  

  • 56. Gene Electrotransfer: A Mechanistic Perspective.
    Rosazza C; Meglic SH; Zumbusch A; Rols MP; Miklavcic D
    Curr Gene Ther; 2016; 16(2):98-129. PubMed ID: 27029943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Successive site translocating inoculation potentiates DNA/recombinant vaccinia vaccination.
    Ren Y; Wang N; Hu W; Zhang X; Xu J; Wan Y
    Sci Rep; 2015 Dec; 5():18099. PubMed ID: 26667202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA is an efficient booster of dendritic cell-based vaccine.
    Li J; Valentin A; Beach RK; Alicea C; Felber BK; Pavlakis GN
    Hum Vaccin Immunother; 2015; 11(8):1927-35. PubMed ID: 26125100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Electroporation-mediated administration of candidate DNA vaccines against HIV-1.
    Vasan S
    Methods Mol Biol; 2014; 1121():291-307. PubMed ID: 24510833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.